Several studies investigating the role of anti-TNF-α therapy in modulating the consequences of IBD by different mechanisms as inhibiting activation of immune cells [36], downregulates the expression of cell adhesion molecules and proinflammatory cytokines [37] and has a favorable effect on the gut microbiome [38]. The gene discussed is TNF; the disease is irritable bowel syndrome.